BR112021014068A2 - Plasminogênio para tratamento e prevenção de microtrombose - Google Patents

Plasminogênio para tratamento e prevenção de microtrombose Download PDF

Info

Publication number
BR112021014068A2
BR112021014068A2 BR112021014068-9A BR112021014068A BR112021014068A2 BR 112021014068 A2 BR112021014068 A2 BR 112021014068A2 BR 112021014068 A BR112021014068 A BR 112021014068A BR 112021014068 A2 BR112021014068 A2 BR 112021014068A2
Authority
BR
Brazil
Prior art keywords
plasminogen
patient
plg
administration
use according
Prior art date
Application number
BR112021014068-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Stephan T. Kiessig
Ricarda Welz
Hanne Rieke GERDING
Marc MAZUR
Hans-Joachim Anders
Chongxu Shi
Christoph Schimmelpfennig
Satish Kumar Devarapu
Original Assignee
Previpharma Consulting Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Previpharma Consulting Gmbh filed Critical Previpharma Consulting Gmbh
Publication of BR112021014068A2 publication Critical patent/BR112021014068A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021014068-9A 2019-01-24 2020-01-24 Plasminogênio para tratamento e prevenção de microtrombose BR112021014068A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19153572.3 2019-01-24
EP19153572 2019-01-24
PCT/EP2020/051733 WO2020152322A1 (en) 2019-01-24 2020-01-24 Plasminogen for treating and preventing microthrombosis

Publications (1)

Publication Number Publication Date
BR112021014068A2 true BR112021014068A2 (pt) 2021-09-21

Family

ID=65234430

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021014068-9A BR112021014068A2 (pt) 2019-01-24 2020-01-24 Plasminogênio para tratamento e prevenção de microtrombose

Country Status (9)

Country Link
US (1) US20220072110A1 (https=)
EP (1) EP3914288A1 (https=)
JP (1) JP2022518496A (https=)
KR (1) KR20210119428A (https=)
CN (1) CN113597313A (https=)
AU (1) AU2020212404B2 (https=)
BR (1) BR112021014068A2 (https=)
CA (1) CA3127375A1 (https=)
WO (1) WO2020152322A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022258590A1 (en) 2021-06-08 2022-12-15 Previpharma Consulting Gmbh Process for isolating plasminogen from a blood plasma fraction
WO2025132796A1 (en) 2023-12-21 2025-06-26 Previpharma Consulting Gmbh Process for isolating glu-plasminogen from a solution

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (https=) * 1973-12-18 1977-04-22 Choay Sa
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
ES2982294T3 (es) * 2015-12-18 2024-10-15 Talengen Int Ltd Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus
ES2968254T3 (es) * 2015-12-18 2024-05-08 Talengen Int Ltd Plasminógeno para su uso en la prevención o el tratamiento de la trombosis aguda y la trombosis crónica
DK3391902T5 (da) * 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
KR102640024B1 (ko) * 2017-03-09 2024-02-22 프리비파하르마, 컨설팅 게엠베하 혈액 분획으로부터의 Glu-플라스미노겐의 제조 및 용도

Also Published As

Publication number Publication date
AU2020212404B2 (en) 2025-11-27
WO2020152322A1 (en) 2020-07-30
KR20210119428A (ko) 2021-10-05
JP2022518496A (ja) 2022-03-15
EP3914288A1 (en) 2021-12-01
US20220072110A1 (en) 2022-03-10
CN113597313A (zh) 2021-11-02
AU2020212404A1 (en) 2021-08-26
CA3127375A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
Majeed et al. Bleeding and antidotes in new oral anticoagulants
Lambourne et al. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate
Saxonhouse et al. The evaluation and management of neonatal coagulation disorders
US20100062981A1 (en) Use of fibrinogen as a prophylactic treatment to prevent bleeding during and after surgery and as a biomarker to identify patient with an increased risk for excessive bleeding and blood transfusion
McKenna Abnormal coagulation in the postoperative period contributing to excessive bleeding
Larsson et al. Valproic acid selectively increases vascular endothelial tissue‐type plasminogen activator production and reduces thrombus formation in the mouse
Plautz et al. Von Willebrand factor as a thrombotic and inflammatory mediator in critical illness
CN110612350A (zh) 源自血液的谷氨酸-纤溶酶原的制备和使用
US12590301B2 (en) Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase
BR112021014068A2 (pt) Plasminogênio para tratamento e prevenção de microtrombose
Sidelmann et al. Orthognathic surgery-induced fibrinolytic shutdown is amplified by tranexamic acid
LeVeen et al. Coagulopathy post peritoneovenous shunt
Galhardo Jr et al. Clinical protocols for oral anticoagulant reversal during high risk of bleeding for emergency surgical and nonsurgical settings: a narrative review
RU2813699C2 (ru) Плазминоген для лечения и профилактики микротромбоза
Tang et al. Factor XIII deficiency does not prevent FeCl3‐induced carotid artery thrombus formation in mice
Sartori et al. Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center
Le Sache et al. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit
Sniecinski et al. Managing clotting: a North American perspective
Di Perri et al. Defibrotide therapy for thrombophlebitis–controlled clinical trial
JP2012519674A (ja) フィブリノーゲンの新規な使用
Brown et al. Anticoagulation
Tang et al. Factor XIII deficiency does not prevent FeCl
Plautz et al. SUPPLEMENT ARTICLE
Manzato et al. Emergency management of patients being treated with oral anticoagulants
Bonanno Coagulopathies in Trauma and Major Bleeding–a clinical perspective